Skip header and navigation

Refine By

99 records – page 1 of 10.

[10-year cytodiagnosis of cervical carcinoma: results and further developments].

https://arctichealth.org/en/permalink/ahliterature111744
Source
Geburtshilfe Frauenheilkd. 1966 Aug;26(8):1135-44
Publication Type
Article
Date
Aug-1966

Accuracy and false-positive rate of the cytologic diagnosis of follicular cervicitis: observations from the College of American Pathologists Pap Educational Program.

https://arctichealth.org/en/permalink/ahliterature112651
Source
Arch Pathol Lab Med. 2013 Jul;137(7):907-11
Publication Type
Article
Date
Jul-2013
Author
Manon Auger
Walid Khalbuss
Ritu Nayar
Chengquan Zhao
Patricia Wasserman
Rhona Souers
Nicole Thomas
Ann T Moriarty
Author Affiliation
Department of Pathology, McGill University and McGill University Health Center, Montreal, Quebec H3A 2B4, Canada.
Source
Arch Pathol Lab Med. 2013 Jul;137(7):907-11
Date
Jul-2013
Language
English
Publication Type
Article
Keywords
Adenocarcinoma - diagnosis - epidemiology
Canada - epidemiology
Carcinoma, Squamous Cell - diagnosis - epidemiology
Cervical Intraepithelial Neoplasia - diagnosis - epidemiology
False Positive Reactions
Female
Humans
Papanicolaou test
Reproducibility of Results
Retrospective Studies
Societies, Medical
United States - epidemiology
Uterine Cervical Neoplasms - diagnosis - epidemiology
Uterine Cervicitis - diagnosis - epidemiology
Vaginal Smears - methods - standards
Abstract
Follicular cervicitis is usually easily identifiable on Papanicolaou (Pap) tests; however, historically, follicular cervicitis is reported to lead to false-positive diagnoses of epithelial cell abnormalities.
To assess participant responses in the College of American Pathologists (CAP) Pap educational program (CAP-PAP) to determine the accuracy and false-positive rate of follicular cervicitis cases. Design.-We performed a retrospective review of 4914 participant responses for gynecologic cytology challenges with the reference diagnosis of follicular cervicitis during 11 years (2000-2010) from CAP-PAP. Reference diagnosis category, false-positive rates by participant type (laboratory, cytotechnologist, pathologist), and preparation type (conventional smears, ThinPrep) were analyzed.
Of the total 4914 general category responses, 4368 (88.9%) were benign while 546 (11.1%) responses were epithelial cell abnormalities (false positives). Of benign responses, only 2026 (46.4%) were an exact match to follicular cervicitis. Adenocarcinoma and high-grade squamous intraepithelial lesion were the most common diagnoses chosen as a false-positive interpretation (42.3% and 20.1%, respectively). Participant type was significantly associated with false-positive interpretations (laboratory: 19.2%; cytotechnologist: 11.1%; pathologist: 7.9%; P
PubMed ID
23808462 View in PubMed
Less detail

Adenocarcinoma of the anal ducts. A series of 21 cases.

https://arctichealth.org/en/permalink/ahliterature25879
Source
Dis Colon Rectum. 1988 Apr;31(4):268-72
Publication Type
Article
Date
Apr-1988
Author
S L Jensen
M H Shokouh-Amiri
K. Hagen
H. Harling
O V Nielsen
Author Affiliation
Department of Surgical Gastroenterology C, Rigshospitalet, University of Copenhagen, Denmark.
Source
Dis Colon Rectum. 1988 Apr;31(4):268-72
Date
Apr-1988
Language
English
Publication Type
Article
Keywords
Adenocarcinoma - diagnosis - mortality - surgery
Adult
Aged
Aged, 80 and over
Anus Neoplasms - diagnosis - mortality - surgery
Denmark
Female
Follow-Up Studies
Humans
Male
Middle Aged
Abstract
The records of 21 patients treated for adenocarcinoma of the anal ducts between 1943 and 1982 were reviewed. The patients were followed until death or current status in April 1987. The median follow-up period was eight months (range, 3 to 144 months). Fifteen patients had an erroneous diagnosis made at first physician visit resulting in a median doctor's delay of 14 months (range, 3 to 24 months) before correct treatment was carried out. Nine of the tumors were localized perianally (ischiorectal space), seven anally, and five in a fistula-in-ano. Tumors localized anally were significantly smaller and had a significantly shorter history than perianally or fistula-in-ano localized tumors (P less than .05 for each localization). Three patients with anal tumors had their diagnosis made accidentally by routine histologic examination of an excised hemorrhoid. First examination revealed distant metastases in 13 patients and follow-up examination revealed regional or distant metastases in seven patients. Modes of treatment were wide local excision (N = 3), abdominoperineal resection (N = 3), colostomy (N = 9), and radiotherapy (N = 2). Twenty of the 21 patients died within 18 months due to the cancer. One long-term survivor was observed; the patient was alive 12 years after local excision of the tumor without evidence of recurrent disease. The crude five- and 10-year survival was only 4.8 percent.
PubMed ID
3359895 View in PubMed
Less detail

Adenocarcinoma of the fallopian tube. Experience with 41 patients.

https://arctichealth.org/en/permalink/ahliterature249383
Source
Obstet Gynecol. 1977 Dec;50(6):654-7
Publication Type
Article
Date
Dec-1977
Author
J L Benedet
G W White
R N Fairey
D A Boyes
Source
Obstet Gynecol. 1977 Dec;50(6):654-7
Date
Dec-1977
Language
English
Publication Type
Article
Keywords
Adenocarcinoma - diagnosis - drug therapy - mortality - pathology - radiotherapy
Adult
Aged
Antineoplastic Agents - therapeutic use
British Columbia
Dilatation and Curettage
Fallopian Tube Neoplasms - diagnosis - drug therapy - mortality - pathology - radiotherapy
Female
Humans
Middle Aged
Neoplasm Staging
Phosphorus Radioisotopes - therapeutic use
Radiotherapy, High-Energy
Abstract
Forty-one cases of primary fallopian tube carcinoma treated at our institution over the years 1946 to 1976 are described. The overall 5-year survival rate was 34.4%, although patients with early tumors had a 72.7% survival rate. The single most important factor affecting survival appeared to be the extent of disease at the time of diagnosis. Past and present treatment modalities are discussed, and proposals for management of this disease are outlined.
PubMed ID
412144 View in PubMed
Less detail

Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.

https://arctichealth.org/en/permalink/ahliterature81046
Source
Scand J Urol Nephrol. 2006;40(4):265-71
Publication Type
Article
Date
2006
Author
Jonsson E.
Sigbjarnarson H P
Tomasson J.
Benediktsdottir K R
Tryggvadottir L.
Hrafnkelsson J.
Olafsdottir E J
Tulinius H.
Jonasson J G
Author Affiliation
Department of Urology, Landspitali University Hospital, Faculty of Medicine, University of Iceland, Reykjavik, Iceland. eirikjon@lanspitali.is
Source
Scand J Urol Nephrol. 2006;40(4):265-71
Date
2006
Language
English
Publication Type
Article
Keywords
Adenocarcinoma - diagnosis - epidemiology - pathology - therapy
Aged
Aged, 80 and over
Follow-Up Studies
Humans
Iceland - epidemiology
Male
Middle Aged
Multivariate Analysis
Neoplasm Staging
Prostatic Neoplasms - diagnosis - epidemiology - pathology - therapy
Registries
Survival Analysis
Abstract
OBJECTIVE: To investigate adenocarcinoma of the prostate in a single population with an extended follow-up period. MATERIAL AND METHODS: Using the Icelandic Cancer Registry, we identified all Icelandic men diagnosed with prostate cancer between 1983 and 1987. Disease stage, initial treatment and follow-up information were obtained from hospital records and death certificates. A critical evaluation was made of the accuracy of the death certificates regarding prostate cancer. All available histology information was reviewed and graded according to the Gleason grading system. RESULTS: A total of 414 men were diagnosed with adenocarcinoma of the prostate. Of these, 370 were alive at the time of diagnosis and stage could be determined. Four stage groups were defined: focal incidental (n=50); localized (n=164); local advanced (n=32); and metastatic disease (n=124). The mean age at diagnosis was 74.4 years (range 53-94 years). The combined Gleason score was 2-5 in 89, 6-7 in 117, 8-10 in 117 and unknown in 47 cases. The median follow-up period for the group was 6.15 years (range 0.3-19.8 years). Thirty men received treatment with curative intent: radiation therapy, n=20; and radical prostatectomy, n=10. A total of 334 patients died during the follow-up period, of whom 168 (50%) died of prostate cancer. Prostate cancer-specific survival at 10 and 15 years was 100% and 90.6%, respectively for focal incidental cancer; 73.1% and 60.8% for men with localized disease; 23.4% and 11.7% for local advanced disease; and 6.81% and 5.45% for metastatic disease. A Cox multivariate analysis showed age, stage and Gleason score to be independent predictors of prostate cancer death. A total of 104 patients with localized disease and a Gleason score of
PubMed ID
16916765 View in PubMed
Less detail

Barrett's esophagus: is it all that bad?

https://arctichealth.org/en/permalink/ahliterature201772
Source
Can J Gastroenterol. 1999 Jun;13(5):385-8
Publication Type
Article
Date
Jun-1999
Author
G N Tytgat
Author Affiliation
Academic Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands. g.n.tytgat@amc.uva.nl
Source
Can J Gastroenterol. 1999 Jun;13(5):385-8
Date
Jun-1999
Language
English
Publication Type
Article
Keywords
Adenocarcinoma - diagnosis - epidemiology - etiology
Barrett Esophagus - complications - diagnosis
Canada - epidemiology
Costs and Cost Analysis
Esophageal Neoplasms - diagnosis - epidemiology - etiology
Esophagoscopy
Female
Humans
Incidence
Male
Mass Screening - economics
Risk assessment
Sensitivity and specificity
Survival Rate
Abstract
An alarmingly rapid rise in the number of adenocarcinomas at the level of the gastroesophageal junction and distal esophagus has been noted over the past two decades. Intestinal metaplasia is considered to be the main precursor lesion for such adenocarcinomas. Given the low five-year survival rate in patients with advanced esophageal cancer, strategies for early detection have been developed. Because superficial cancers only rarely cause symptoms, detection of cancer at such an early curable state can only be achieved through surveillance of patients at risk. Therefore, implementation of an endoscopic surveillance program for patients in whom intestinal metaplasia has been detected in the distal esophagus or at the esophagogastric junction seems to be a reasonable option.
PubMed ID
10377467 View in PubMed
Less detail
Source
Cancer. 2000 Nov 15;89(10):2076-84
Publication Type
Article
Date
Nov-15-2000
Author
M. Baekelandt
A. Jorunn Nesbakken
G B Kristensen
C G Tropé
V M Abeler
Author Affiliation
Department of Gynecologic Oncology, The Norwegian Radium Hospital, Oslo, Norway.
Source
Cancer. 2000 Nov 15;89(10):2076-84
Date
Nov-15-2000
Language
English
Publication Type
Article
Keywords
Adenocarcinoma - diagnosis - mortality - pathology - secondary
Adult
Aged
Aged, 80 and over
Fallopian Tube Neoplasms - diagnosis - mortality - pathology
Female
Humans
Middle Aged
Multivariate Analysis
Neoplasm Staging
Norway - epidemiology
Postoperative Care
Prognosis
Recurrence
Survival Analysis
Abstract
BACKGROUND: The objective of the current study was to increase insight into the biology of fallopian tube carcinoma through an analysis of possible clinical and pathologic determinants of prognosis and to formulate recommendations with regard to a more optimal therapeutic approach for patients with this rare disease. METHODS: A study was performed of the pathology specimens and clinical case records from 151 patients with fallopian tube carcinoma who were treated consecutively. Both univariate and multivariate analyses of possible prognostic factors were performed for the whole group and for the subgroup of 41 patients with Stage I disease. The possible significance of serum CA-125 levels as a tumor marker and a marker of response to platinum-containing chemotherapy was evaluated. RESULTS: In multivariate analysis, disease stage, the presence of residual tumor, and a hydrosalpinx-like appearance of the fallopian tube were of independent prognostic significance for the whole cohort. For patients with Stage I disease, the depth of infiltration in the tubal wall and intraoperative tumor rupture were of independent prognostic significance. The marked tendency of this disease for extraperitoneal spread, even in apparently early stages, was confirmed. In 37 evaluable, platinum-naïve patients, an overall response rate of 70% was obtained with platinum-based chemotherapy, with a median response duration of 12.5 months. In view of its low efficacy and high rate of serious complications, the use of postoperative radiotherapy in the treatment of patients with fallopian tube carcinoma is no longer recommended. Serum CA-125 level measurements in fallopian tube carcinoma patients have the same significance as tumor and surrogate markers of response as in ovarian carcinoma patients. CONCLUSIONS: Prognostic factors in patients with early stage (Stages 0 and I) fallopian tube carcinoma seem to differ from those in patients with early stage ovarian carcinoma. For patients with more advanced stage disease, due to the striking similarities in prognostic and clinical characteristics between the two diseases, the authors recommend that the treatment and follow-up strategies for patients with ovarian carcinoma be adopted in the management of patients with fallopian tube carcinoma.
PubMed ID
11066048 View in PubMed
Less detail

99 records – page 1 of 10.